A B S T R A C T The imllpatet of clial)etes on cyclic nucleotide-associated meclhanismiis regulating skeletal muscle proteini and aminio acid metal)olism was assessed using epitrochlaris preparations fromi streptozotocin-induced diabetic rats. 1 nl epinephrine inhibited alanine and glutamine release from control preparations,lbult no inhibition wvas observed from diabetic preparations with <0.1 mM. 10 nNI epinephrinie stimulated lactate productioni from control muscle but stimulation in diabetic preparattions was observed only at 0.1 m.N Serotonin inhibited amino acid release and stimulated lactate production equallyl in control and diabetic muscle. 0.1 mMI epinephrine increased eyelic (c)AMIP levels by 360% in control muscles, but these levels were increased only 83% in diabetic muscle. Basal-, fluoride-, and serotonin-stimulated adenylvl cyclase activities were equall in membrane preparations of diabetic and control musele, but epinephrine-stimiiulated adenylyl cyclase was reduced bv 60% in diabetic muscle. Carbavmvlcholine stimulaltion of' alanine and glutatmine release wvas blunted in diabetic preparations.
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Carbamylcholine increased cGCMP levels in control but not in diabetic muscle. In diabetic muscle, guanylyl cyclase activity was 65% of control and the stimulation of cvclase activity by sodium azide was less in diabetic than control preparations. Added cGNIP stimulated alanine and gltatimine release from control, but not from diabetic mutscle. These data stuggest a loss of adrenergic aind cholinergic responsiveness in diabetic muscle. Becauste aimino acid release also showed a decreased responsiveness to aidded cANIP and cGMP, the presenice of other deraingements in the mechanism(s) of cyclic nucleotide regulationi of muscle aimino acid metabolism also seems likely. Dr 
INTRODUCTION
Glucose overproductioni is a fundamental contributor to hyperglycemnia in diabetes imlellitus (1) . This may result in part from increased gluconeogenesis as suggested hy an increased hepatic fractional extraction of alanine, the principal gluconeogenic amiino acid in man (2) . Because alaninie production occurs in peripheral tissues such as skeletal muscle (3) , an accelerated rate of alanine deliverv is essential for continuing alanine availability in diabetes mellitus (4, 5) . Increased alanine release has been observed from muscle preparations of experimentally diabetic rats (4, 6) . Although the amiiiino grotips for nlet alaninle f'orimlatioin froImi gltutamtate and pyrtuvate are most probably derived from the deamiiinatioin of other amino acids, the source of carbon for alanine formation is unclear. This may be contributed by the catabolism of other, protein-derived amino acids, b)y pyruvate formed by glycolysis, or by a combination of 1)oth processes (4, (7) (8) (9) (10) (11) (12) (13) . Because insuilini promiiotes mutscle protein synthesis and also inhibits mutscle protein degradation (14) (15) (16) , increased alatnine release wotuld be expected in an insulin deficiency state stuch as diabetes mellitts. However, the impact of the diabetic state on otlher, noninstulin-dependent mechanismiis that regulate inmuscle protein and aiiiino acid metabolism hals not been investigated in detail. Agonists that alter mtuscle cyclic nucleotide levels also provide important control mechanisms for the regulation of skeletal musele protein and amino acid metabolism. Physiologic levels of adrenergic and serotonergic agonists, acting in association with increatsed initracellulatr levels of cyclic (c)AMlP,l inhibit skeletal mutscle alanine aind gluttami ne formation and release (17) (18) (19) (20) ; physiologic levels of choliniergic agonists acting in association with inereased intracelltu-lar levels of cGMP, stimulate skeletal muscle alanine and glutamine formation and release (21, 22) . The impact of experimental, streptozotocin-induced diabetes on the actions of these agonists on skeletal muscle cyclic nucleotide metabolism and on the formation and release of alanine and glutamine has been investigated using intact rat epitrochlaris skeletal muscle preparations. The implications of these findings are discussed. As described previously (1), epitrochlaris preparations were obtained from streptozotocin-treated (65 mg/kg i.v.) and control Sprague-Dawley rats (Texas Inbred, Houston, Tex.). These preparations remained viable in vitro as judged by phosphocreatine and ATP levels that were not different from levels in vivo. Experimental diabetes in the streptozotocintreated animals was assured by the presence of 2% glucosuria (Diastix, Ames Co., Elkhart, Ind.) for a minimum of 10 d before sacrifice of the animals. Semimicro-and microfluoromnetric enzymatic techniques were used to determine levels of alanine, glutamate, and glutamine in perchloric acid extracts of skeletal muscle and in the incubation media as described previously (17, 19, 20) . cAMP and cGMP were determiiined in trichloroacetic acid extracts of skeletal muscle by double antibody radioimmunoassays using m2-I-labeled tyrosine methyl esters of succinylated cyclic nucleotides (23) (24) (25) . Partial purification of cyclic nucleotides from trichloroacetic acid extracts was obtained by double chromatography over Dowex 50 columns and aluminum oxide (Dow Chemical Co., Midland, Mich.) as described by Birnbaumer (26) for simultaneouis separations of cGMP and cAMP. Tritiated cyclic nucleotides were added to each muscle homogenate to quantitate sample recovery. Although cyclic nucleotide levels were determined after 2, 5, 10, 20, and 60 min of incubation with each agonist, only the data for 2-min incubations with epinephrine and 10-min with serotonin and carbamylvcholine are presented because these periods produced the greatest observed increments in cyclic nucleotide levels. Estimations of adenylyl and guianylyl cyclase activities in skeletal muscle homogenates were based on the determination of the rate of production of [32P] (29) . Statistical assessments of the data were made using Student's t test or analysis of variance as appropriate (30) .
METHODS

RESULTS
Potential impairments of cyclic nucleotide-associated mechanisms controlling protein and amino acid metabolism were investigated in epitrochlaris preparations of control and streptozotocin-diabetic rats. The effect of epinephrine on skeletal muscle alanine and glutamine release was first studied (Fig. 1) . Concentrations of epinephrine as low as 1 nM inhibited alanine and glutamine release from control muscle preparations (P < 0.05), and a 50% inhibition was produced by 10,LM epinephrine. In contrast, significant inhibition of alanine or glutamine formation and release in diabetic preparations was observed only with the highest concentration of epinephrine studied (0.1 mM), which reduced alanine and glutamine release 21 and 14% (P < 0.05 each), respectively. Muscle lactate production was also insensitive to epinephrine. 10 nM epinephrine stimulated (P < 0.05) lactate production from control preparations. On the other hand, basal levels of lactate production from muscles of diabetic animals were 88% that of control rats (P < 0.05), and this was increased only minimally with epinephrine (0.1 mM). In contradistinction, the effects of serotonin, another autacoid that inhibits muscle proteolysis and amino acid release (4) , were of relatively equal magnitude in muscles of diabetic and control rats (Fig. 2) . Serotonin inhibited alanine and glutamine release and also stimulated lactate production to an equal extent in control and diabetic skeletal muscle. With either preparation, 0.1 mM serotonin increased lactate production by 70%. This difference between epinephrine and serotonin action on alanine and glutamine release from diabetic muscle is even more apparent in studies of the total content of alanine and glutamine in tissues plus media after incubation (Table I) . In control studies, both epinephrine (10 ,LM) and serotonin (10 ,uM) reduced total alanine and glutamine equally in preparations from normal rats. However, with preparations from streptozotocin-diabetic rats, epinephrine produced virtually no change in total alanine and glutamine.
Because the action of both epinephrine and serotonin on muscle amino acid formation appears to be mediated by increased intracellular levels of cAMP (17, 19) , the effect of incubation with these agonists on muscle cAMP levels was studied for periods of Epi nephri ne FIGURE 1 Effects of epinephrine on amino acid and lactate release from control and diabetic muscle. Epitrochlaris preparations from control (0) and streptozotocin-diabetic rats (0) were obtained and incubated for 1 Table II , basal-and fluoride-stimulated adenylyl cyclase activities were not different in membranes of diabetic as compared with control preparations. Fluoridestimulated adenylyl cyclase activity was 400% greater than basal cyclase activity (P < 0.01 each). Serotonin increased adenylyl cyclase activity of membranes from control and diabetic muscle by 93 and 132%, respectively (P < 0.01 each). In contrast, epinephrine (10 lOM) stimulated adenylyl cyclase 356% in membranes from control preparations, but only 85% in membranes from diabetic preparations. These data also provide the first demonstration of a serotonin-stimulated adenylyl cyclase in rat skeletal muscle.
To determine whether the diminished epinephrinestimulated adenylyl cyclase in membranes of diabetic muscle was the result of the single concentration of epinephrine studied, adenylyl cyclase activity was determined in the presence of a broad range of epinephrine levels (1 nM through 1 mnM) (Fig. 4) Epitrochlaris preparations of control and streptozotocin-diabetic rats were obtained and incubated for 1 h in media containing epinephrine muscle preparations was also investigated. Dibutyryl cAMP (1 mM) but not butyric acid (data not shown) reduced alanine and glutamine release from control muscle preparations by 51 and 44%, respectively (P < 0.001 each). Similarly, dibutyryl cAMP reduced alanine and glutamine release from preparations of diabetic rats by 42 and 40%, respectively (P < 0.001). Nevertheless, alanine and glutamine release from diabetic muscle remained 93 and 39% greater than from control muscle (P < 0.01 each). Cholinergic agonists, acting by a nicotinic cholinergic receptor and in association with increased cGMP levels, accelerate alanine and glutamine formation and release from muscle (5, 6) . With control preparations (Fig. 5) , carbamylcholine (1 ,uM) increased alanine release by 50% and glutamine release by 41% (P < 0.01 each). Significant stimulation was observed with concentrations as low as 1 nM carbamylcholine (P < 0.05). However, carbamylcholine had no additional effect on the increased rates of alanine and glutamine formation and release in diabetic prepara-482 A. J. Garber tions. Carbamylcholine-stimulated rates of alanine and glutamine formation with control preparations were not different from basal rates of amino acid release from diabetic preparations in the absence ofcarbamylcholine.
The basis for the loss of responsiveness to carbamylcholine in diabetic muscle was next investigated. As shown in Fig. 6 , CGMP levels were 40% lower in skeletal muscle of diabetic as compared with control rats. Carbamylcholine produced a concentrationdependent increase in cGMP levels of control muscle; 10 ,uM carbamylcholine increased cGMP levels by 56% (P < 0.01). However, carbamylcholine had no effect on cGMP levels in diabetic muscle. Guanylyl cyclase activity was determined in muscle membrane preparations of control and diabetic rats. As seen in Table III, 40 ,000 g soluble guanylyl cyclase activity was 33% lower and the particulate activity was 37% lower in diabetic as compared with control skeletal muscle (P < 0.01 each). Sodium azide has been shown to stimulate guanylyl cyclase activity in other tissues (31) . In muscle of control rats, preincubation for 10 min at 32.5°C with sodium azide (5 mM) increased soluble guanylyl cyclase activity by 33% and the particulate activity by 51%. In comparison, the effect of sodium azide on the enzyme activities from diabetic muscle was minimal. The results of cGMP addition on skeletal muscle alanine and glutamine formation and release were also investigated. cGMP increased alanine and glutamine release from muscle of control rats by 40 and 30%, respectively (P < 0.02 each), but did not affect amino acid release from preparations of diabetic rats. cGMP at the same concentration did not alter alanine or glutamine release from muscle of either control or diabetic rats. Values shown are the means (+SEM) for at least six experiments.
Control of Amino Acid Metabolism in Diabetic Muscle
DISCUSSION
Alanine and glutamine formation and release are increased 60 and 40%, respectively, in skeletal muscle of streptozotocin-diabetic rats. This may restult in part from an accelerated degradation of one or more classes of skeletal muscle proteins, from a diminished rate of protein resynthesis, or from a combination of both processes (10, 15, 16) . Although insulin influenices both protein synthesis and protein degradation in skeletal muntiscle and abnormalities of both pathways have been described in experimental diabetes mellitus, potential abnormalities of other factors regulating protein and amino acid metabolism in diabetic muscle have not been fully explored. Catecholamines acting througlh a fB-adrenergic receptor and in association with increased intracellular levels of cAMP are potent inhibitors of alanine and glutamine formation and release from skeletal muscle (17) (18) (19) . Skeletal muscle of diabetic animals showed a marked loss of responsiveness to these effects of catecholamines, because 1,000-to 10,000-fold greater concentrations of epinephrine were required to alter amino acid release or lactate production with diabetic as compared with control imuscles (Fig. 1) . These findings are in contrast to the unaltered effects of serotonin on amino acid release and lactate produiction from diabetic skeletal m11us-cle (Fig. 2 ). These differences in responsiveness to epinephrine and serotonin do not derive from an alteratioin of amiiino acid transport (Table I) , or from alltered amino acid reutilization by oxidation to CO2 or by reincorporation into protein because the latter pathways are not quantitatively substantial compared witlh amino acid release (20) . Thus, it seems likely that the diminiislhed responsiveness of amino acid release to epinepl rine derives from a failure to inhibit alanine aind glutamine formationi in diabetic muscle. Becauise this effect of epinephrine appears to be mediated bL increased cAMP levels in normal muscle, the relative inability of epinephrine to stimulate cAMP accumulation in diabetic muscle (Fig. 3 ) may account in plart for the insensitivity of amino acid formation. The diminished epinephrine stimulation of cAMP acctumulation in diabetic muiscle most probably derives from the redtuced epinephrine-stimulated adenylyl cyclase activity in membranes of diabetic mutscles (Table II) . Althoughi basal-, fluoride-, and serotoninstimutlatecI adenylyl cyclase activities were approximnately e(quial in membranes of diabetic as comparedl with control muscle (Table II, Fig. 4 ), epinephrine stimulationi of adenylyl cyclase activity was 80% less in diabetic membranes. The dose-respoinse cutrve of 484
A. J. Garber CarbamyIchol ine FIGURE 6 Effect of carbamylcholine on cGMP levels in skeletal muscle of control and diabetic rats. Epitrochlaris preparations from streptozotocin-induced diabetic (0) and control (0) rats were obtained and incubated for 10 min in Krebs-Henseleit media containing glucose (5 mM) and carbamylcholine added at the concentrations shown. After incubation, muscles were rapidly removed, rinsed, blotted, and frozen in liquid nitrogen. Levels of cGMP were determined on the trichloracetic extracts of each muscle preparation using double antibody radioimmunoassay techniques as outlined in Methods. Values shown are the means (+SEM) for at least eight experiments. adenylyl cyclase stimulation by epinephrine was blunted and shifted 3 log-unit intervals, which corresponds reasonably well to the shift of the doseresponse curve of cAMP accumulation in the intact muscle (Fig. 3) . Furthermore, preliminary assessments of cAMP phosphodiesterase activities revealed no difference between control and diabetic muscle.2 These observations support the concept that a diminished epinephrine-stimulated adenylyl cyclase activity may account primarily for the decreased epinephrine-induced cAMP accumulation in diabetic muscle. However, the data do not provide a precise mechanism for this reduction. Although basal-, fluoride-, and serotonin-stimulated adenylyl cyclase activities were unchanged, a uniform reduction in the amount of adenylyl cyclase enzyme or the presence of an acquired inhibitor appears to be somewhat unlikely based upon these data using an in vitro enzyme assay system. Because serotonin stimulation of adenylyl cyclase was unaltered in diabetic muscle, abnormal nucleotide regulation of the basic adenylyl cyclase system, or an abnormal capacity of adenylyl cyclase to couple to receptors in diabetes also appears unlikely, assuming that the mechanism of epinephrine and serotonin stimulation of adenylyl cyclase are similar. A decreased number of adrenergic receptors, an altered receptor affinity for catecholamines, or an altered capacity of the ,-adrenergic receptor to couple to an otherwise normal adenylyl cyclase appear to be the most probable reasons for the diminished epinephrine-stimulated adenylyl cyclase activity. These results may be interpreted to suggest a loss of adrenergic responsiveness or desensitization (20, 32, 33) ; this may be similar to the desensitization found in the pseudodiabetic azotemic state (20) , in which abnormalities of both serotoninand epinephrine-stimulated adenylyl cyclase were observed. Although the data of the present study do not provide insight into the means by which adrenergic but not serotonergic responsiveness is lost in diabetic 2 Garber, A. J., M. L. Entman, E. P. Bornet, and W. J.
Thompson. Unpublished observations. (34) , and these may contribute to the loss of adrenergic responsiveness via homologous desensitization. In diabetic muscle, the dose-responsive curve of amino acid release to catecholamines was shifted 5 log-unit intervals, whereas cAMP accumulation and adenylyl cyclase stimulation were shifted 3 log units. Furthermore, neither serotonin nor dibutyryl cAMP completely normalized alanine and glutamine release from diabetic as compared with control muscle under the same incubation conditions. Although the absolute reductions in alanine and glutamine release produced by serotonin or dibutyryl cAMP were similar, amino acid release from diabetic muscle remained elevated by 50-100%. At any level of cAMP, higher rates of amino acid formation and release were observed in diabetic as compared with control preparations. Factors in addition to the loss of adrenergic responsiveness must also participate in the accelerated alanine and glutamine formation in diabetic muscle. Nevertheless, at concentrations of epinephrine and serotonin producing equal stimulation of cAMP levels, serotonin did cause slightly greater inhibition of alanine and glutamine output from diabetic muscle. Thus, the data of the present study do not exclude differences in cAMP compartmentation or in cAMPdependent protein kinase regulation between serotonin and epinephrine action in diabetic as contrasted to control muscle. In the past we have shown that muscle glutamine and alanine formation can be increased by nicotinic cholinergic stimulation associated with elevation of cGMP levels (21, 22) . Nevertheless, the abnormal cholinergic responsiveness observed in diabetic muscle does not account for the increased alanine and glutamine release from diabetic muscle. Although carbamylcholine did not further stimulate alanine and glutamine release in diabetic muscle (Fig. 5) , decreased cGMP levels were found and these levels were unresponsive to carbamylcholine, presumably a result of the diminished guanylyl cyclase activity. Based on these results, it is not possible to account for the increased alanine and glutamine release from diabetic muscle because decreased rather than increased rates of amino acid release would have been anticipated as the result of the lower cGMP levels. Although these abnormalities of guanylyl cyclase in diabetic muscle are similar to an abnormality found in diabetic liver (35) , the basis for that effect is not apparent from the data of the present study.
Diabetes mellitus is characterized by a relative or absolute insulin deficiency that may result in accelerated muscle proteolysis and amino acid release (4, 8, 16) . The findings of the present study demonstrate abnormalities of adrenergic and cholinergic regulation of protein and amino acid metabolism in diabetic muscle. Increased as well as decreased cAMP levels and catecholamine-stimulated adenylyl cyclase activities have been observed in a number of tissues obtained from a variety of diabetic models (36) (37) (38) (39) . The present finding of a subsensitivity of muscle amino acid release to physiologic levels of catecholamines provides a mechanism in addition to insulin deficiency that may thereby cause glucose overproduction in diabetic man, because physiologic levels of catecholamines (0.1-10 nM) would be ineffective in restraining the accelerated rates of muscle alanine delivery in vivo as a result of this desensitization process (34, 40) .
